| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
o-Hydroxybenzylamine targets reactive dicarbonyls, specifically γ-ketoaldehydes (γKAs) and isolevuglandins (IsoLGs). These are reactive lipid oxidation products that can form adducts with proteins, contributing to oxidative stress and inflammation. By scavenging these reactive species, o-Hydroxybenzylamine protects cells from their deleterious effects. It is a selective dicarbonyl scavenger with potent antioxidant activity. Its mechanism does not involve a specific protein target but rather the chemical neutralization of reactive carbonyls.
|
|---|---|
| ln Vitro |
In vitro, o-Hydroxybenzylamine acts as a potent scavenger of γ-ketoaldehydes (γKAs), protecting cells from γKA adduct formation. It is an antioxidant and scavenger of free radicals and isolevuglandins (IsoLGs). These activities make it a valuable tool for studying oxidative stress and inflammation in cell-based models. It can be used to investigate the role of reactive dicarbonyls in various disease processes.
|
| ln Vivo |
In vivo, o-Hydroxybenzylamine has been studied for its potential protective effects in models of inflammation and cardiovascular disease. Its ability to scavenge reactive dicarbonyls may reduce oxidative damage and inflammation. However, specific in vivo efficacy data are not extensively detailed in the available literature. The compound is used in research on atherosclerosis, atrial fibrillation, and arrhythmias.
|
| Enzyme Assay |
In vitro assays for o-Hydroxybenzylamine measure its ability to scavenge reactive dicarbonyls such as γ-ketoaldehydes (γKAs) and isolevuglandins (IsoLGs). The compound's scavenging activity can be assessed using competitive binding assays or by measuring the formation of protein adducts in the presence of the compound. Antioxidant activity can be measured using standard assays such as DPPH or ABTS radical scavenging.
|
| Cell Assay |
Cell-based assays for o-Hydroxybenzylamine are conducted in cell lines relevant to inflammation and cardiovascular disease. Cells are treated with the compound and exposed to oxidative stress or inflammatory stimuli. Markers of oxidative damage, inflammation, and cell viability are measured. The compound's ability to protect cells from γKA adduct formation can be assessed. These assays characterize its cytoprotective and antioxidant effects.
|
| Animal Protocol |
In vivo animal experiments with o-Hydroxybenzylamine are conducted in models of cardiovascular disease and inflammation. The compound is administered orally or intraperitoneally, and endpoints such as inflammatory markers, oxidative damage, and disease progression are assessed. Specific protocols depend on the disease model being studied. The compound is for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of o-Hydroxybenzylamine are not extensively characterized. The compound has a molecular formula of C7H9NO and a molecular weight of 123.15. It is soluble in DMSO and water. Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months. Specific data on absorption, distribution, metabolism, and excretion are not available.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for o-Hydroxybenzylamine are limited. As an antioxidant and dicarbonyl scavenger, it is expected to have low toxicity. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed. No specific toxicity data are available.
|
| References |
|
| Additional Infomation |
2-(aminomethyl)phenol is being investigated in the clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Elderly). Buckwheat and Michelia champaca have been reported to contain 2-(aminomethyl)phenol, and relevant data are available.
o-Hydroxybenzylamine has CAS number 932-30-9, molecular formula C7H9NO, and molecular weight 123.15. It is a selective dicarbonyl scavenger, antioxidant, and scavenger of free radicals and IsoLGs. It scavenges γKAs 980-fold faster than adduct formation. It is used in inflammation and cardiovascular disease research. Purity: typically ≥98%. Not for human use; for research purposes only. |
| Molecular Formula |
C7H9NO
|
|---|---|
| Molecular Weight |
123.1525
|
| Exact Mass |
123.068
|
| CAS # |
932-30-9
|
| PubChem CID |
70267
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
245.0±15.0 °C at 760 mmHg
|
| Melting Point |
127-131ºC
|
| Flash Point |
102.0±20.4 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
0.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
85
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KPRZOPQOBJRYSW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO/c8-5-6-3-1-2-4-7(6)9/h1-4,9H,5,8H2
|
| Chemical Name |
2-(aminomethyl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~406.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (20.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (20.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1202 mL | 40.6009 mL | 81.2018 mL | |
| 5 mM | 1.6240 mL | 8.1202 mL | 16.2404 mL | |
| 10 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
